期刊文献+

基于水解酶的抗寄生虫前药研究

Progress on Hydrolases-targeting Antiparasitic Prodrugs
下载PDF
导出
摘要 前药策略已被广泛应用于各种基于药剂学、药代动力学和药效学的药物优化。多数涉及前药转化的酶都属于水解酶,其中以酯水解酶和酰胺水解酶的研究最为广泛。本文综述了基于这两种水解酶的抗寄生虫前药的研究进展。 Prodrug strategies have been used for drug optimization to overcome the drawbacks in pharmaceutics,pharmacokinetics and pharmacodynamics.Most enzymes involved in prodrug biotransformation are hydrolases,in which esterase and amidase have been widely researched.This review summarizes the recent progress in antiparasitic prodrugs based on both targets.
出处 《中国寄生虫学与寄生虫病杂志》 CAS CSCD 北大核心 2012年第2期139-145,共7页 Chinese Journal of Parasitology and Parasitic Diseases
关键词 前药 水解酶 酯水解酶 酰胺水解酶 抗寄生虫药 Prodrug Hydrolase Esterase Amidase Antiparasitic drug
  • 相关文献

参考文献66

  • 1Stella VJ,Borchardt RT,Hageman MJ,et al.Prodrugs:Chal-lenges and Rewards[M].USA:Springer,2007.
  • 2Han HK,Amidon GL.Targeted prodrug design to optimize drug delivery[J].AAPS J,2002,2(1):48-58.
  • 3Singh C,Chaudhary S,Puri SK.Orally active esters of dihydroartemisinin:Synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in mice[J].Bioorg Med Chem Lett,2008,18(4):1436-1441.
  • 4Testa B.Prodrugs:bridging pharmacodynamic/pharmacokinetic gaps[J].Curr Opin Chem Biol,2009,13(3):338-344.
  • 5Rautio J,Kumpulainen H,Heimbach T,et al.Prodrugs:de-sign and clinical applications[J].Nat Rev Drug Discov,2008,7(3):255-270.
  • 6Ettmayer P,Amidon GL,Clement B,et al.Lessons learned from marketed and investigational prodrugs[J].J Med Chem,2004,47(10):2393-2404.
  • 7Müller CE.Prodrug approaches for enhancing the bioavailability of drugs with low solubility[J].Chem Biodivers,2009,6(11):2071-2083.
  • 8Miwa M,Ura M,Nishida M,et al.Design of a novel oral fluoropyrimidine carbamate,capecitabine,which generates5-flu-orouracil selectively in tumours by enzymes concentrated in hu-man liver and cancer tissue[J].Eur J Cancer,1998,34(8):1274-1281.
  • 9Walko CM,Lindley C.Capecitabine:a review[J].Clin Ther,2005,27(1):23-44.
  • 10Comella P.A review of the role of capecitabine in the treat-ment of colorectal cancer[J].Ther Clin Risk Manag,2007,3(3):421.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部